Larynx Cancer

Categories: Cancer diseases, Oral diseases, Rare diseases, Respiratory diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Larynx Cancer

MalaCards integrated aliases for Larynx Cancer:

Name: Larynx Cancer 11 14
Laryngeal Carcinoma 11 19 75 53 14
Laryngeal Cancer 19 53 75
Malignant Neoplasm of Larynx 71 31
Carcinoma of Larynx 11 71
Laryngeal Neoplasm 16 71
Laryngeal Neoplasms 43
Cancer, Laryngeal 38
Cancer of Larynx 11


External Ids:

Disease Ontology 11 DOID:2596 DOID:2600
ICD9CM 34 161
MeSH 43 D007822
NCIt 49 C4855 C7484
SNOMED-CT 68 154480006 93859007
ICD10 31 C32 C32.9
UMLS 71 C0007107 C0023055 C0595989

Summaries for Larynx Cancer

Disease Ontology 11 Larynx cancer: A respiratory system cancer that is located in the larynx.

Laryngeal carcinoma: A larynx cancer that has material basis in epithelial cells.

MalaCards based summary: Larynx Cancer, also known as laryngeal carcinoma, is related to laryngeal benign neoplasm and laryngeal squamous cell carcinoma. An important gene associated with Larynx Cancer is MIR21 (MicroRNA 21), and among its related pathways/superpathways are Nuclear receptors meta-pathway and Malignant pleural mesothelioma. The drugs Nicotinamide and Docetaxel have been mentioned in the context of this disorder. Affiliated tissues include larynx, lymph node and lung, and related phenotype is neoplasm.

GARD: 19 A carcinoma of the larynx.

Wikipedia: 75 Laryngeal cancers are mostly squamous-cell carcinomas, reflecting their origin from the epithelium of... more...

Related Diseases for Larynx Cancer

Diseases in the Larynx Cancer family:

Larynx Carcinoma in Situ

Diseases related to Larynx Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 653)
# Related Disease Score Top Affiliating Genes
1 laryngeal benign neoplasm 31.7 TP53 MIR106B EGFR CCND1
2 laryngeal squamous cell carcinoma 30.9 TP53 TERT NME1 MKI67 MIR21 MIR139
3 keratoacanthoma 30.8 TP53 MKI67 EGFR BCL2
4 squamous cell carcinoma 30.8 TP53 TERT NME1 MKI67 GSTP1 EGFR
5 small cell cancer of the lung 30.6 TP53 MIR21 EGFR BCL2
6 suppressor of tumorigenicity 3 30.6 TP53 BCL2
7 adenoid cystic carcinoma 30.5 TP53 MKI67 EGFR CCND1 BCL2
8 hypopharynx cancer 30.5 TP53 NME1 MIR143 EGFR CCND1 BCL2
9 papilloma 30.5 TP53 GSTP1 EGFR CCND1 BCL2
10 b-cell lymphoma 30.4 TP53 MKI67 GSTP1 CCND1 BCL2
11 head and neck cancer 30.4 TP53 MIR486-1 MIR31 MIR21 MIR145 MIR143
12 lip and oral cavity cancer 30.4 TP53 MIR31 MIR21 GSTM3 GSTM1 EGFR
13 gastroesophageal reflux 30.4 TP53 TERT MKI67 EGFR CCND1 BCL2
14 colon adenocarcinoma 30.3 TP53 MKI67 EGFR CCND1 BCL2
15 pharynx cancer 30.3 MIR486-1 MIR31 MIR21 MIR148A MIR145 MIR143
16 skin carcinoma 30.3 TP53 MIR31 MIR21 EGFR CCND1 BCL2
17 keratosis 30.3 TP53 EGFR BCL2
18 inverted papilloma 30.3 TP53 MKI67 CCND1
19 adenoma 30.3 TP53 MKI67 CCND1 BCL2
20 skin squamous cell carcinoma 30.3 TP53 MIR21 EGFR CCND1
21 breast adenocarcinoma 30.2 TP53 EGFR CCND1 BCL2
22 acquired immunodeficiency syndrome 30.2 TP53 GSTM1 CCND1 BCL2
23 lung benign neoplasm 30.2 TP53 TERT GSTP1 EGFR
24 spinal cord disease 30.2 TP53 TERT MIR139 MIR106B EGFR
25 laryngeal disease 30.2 MIR486-1 MIR31 MIR21 MIR148A MIR145 MIR143
26 large cell carcinoma 30.2 TP53 MIR31 MIR145 EGFR
27 myocardial infarction 30.2 TP53 MIR486-1 MIR21 MIR145 MIR143 MIR139
28 cervical adenocarcinoma 30.2 TP53 NME1 MKI67
29 cervical cancer 30.1 TP53 TERT NME1 MIR31 MIR21 MIR143
30 esophagus adenocarcinoma 30.1 TP53 MIR21 MIR145 MIR143 EGFR CCND1
31 lung squamous cell carcinoma 30.1 TP53 MIR145 MIR139 EGFR
32 oral cavity cancer 30.1 MIR486-1 MIR31 MIR21 MIR145 MIR143 MIR139
33 leiomyosarcoma 30.1 TP53 CCND1 BCL2
34 oropharynx cancer 30.1 TP53 MIR486-1 MIR21 MIR139 EGFR CCND1
35 kidney cancer 30.1 TP53 MIR21 MIR145 MIR106B GSTP1 EGFR
36 pancreatic adenocarcinoma 30.1 TP53 EGFR CCND1 BCL2
37 wilms tumor 1 30.1 TP53 TERT EGFR CCND1 BCL2
38 lynch syndrome 30.1 TP53 TERT MIR31 MIR139 EGFR CCND1
39 thyroid gland anaplastic carcinoma 30.1 TP53 TERT MIR145 EGFR CCND1 BCL2
40 cholangiocarcinoma 30.1 TP53 TERT MIR21 MIR148A EGFR CCND1
41 tongue carcinoma 30.1 TP53 TERT MIR31 MIR21 MIR143 MIR139
42 myeloma, multiple 30.1 TP53 MIR21 MIR145 MIR106B CCND1 BCL2
43 transitional cell carcinoma 30.1 TP53 NME1 MKI67 GSTP1 GSTM1 EGFR
44 basal cell carcinoma 30.1 TP53 MKI67 GSTP1 GSTM3 GSTM1 EGFR
45 colonic benign neoplasm 30.1 TP53 MIR21 MIR145 MIR143 EGFR CCND1
46 rhabdomyosarcoma 30.0 TP53 TERT EGFR CCND1 BCL2
47 human papillomavirus infectious disease 30.0 TP53 TERT MIR486-1 MIR31 MIR21 MIR139
48 glioblastoma 30.0 TP53 TERT MIR486-1 MIR21 EGFR CCND1
49 nasopharyngeal carcinoma 30.0 TP53 TERT NME1 MIR486-1 MIR31 MIR21
50 peripheral nervous system disease 30.0 TP53 TERT MIR486-1 MIR31 MIR21 MIR145

Comorbidity relations with Larynx Cancer via Phenotypic Disease Network (PDN):

Bronchitis Deficiency Anemia
Pharynx Cancer Protein-Energy Malnutrition
Respiratory Failure Supraglottis Cancer
Swallowing Disorders

Graphical network of the top 20 diseases related to Larynx Cancer:

Diseases related to Larynx Cancer

Symptoms & Phenotypes for Larynx Cancer

MGI Mouse Phenotypes related to Larynx Cancer:

# Description MGI Source Accession Score Top Affiliating Genes
1 neoplasm MP:0002006 9.32 BCL2 CCND1 EGFR GSTP1 MIR139 MIR31

Drugs & Therapeutics for Larynx Cancer

Drugs for Larynx Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 168)
# Name Status Phase Clinical Trials Cas Number PubChem Id
Nicotinamide Approved, Investigational Phase 3 98-92-0 936
Docetaxel Approved, Investigational Phase 3 114977-28-5 148124
Cefazolin Approved Phase 3 25953-19-9 33255
Fluorouracil Approved Phase 3 51-21-8 3385
Hydroxyurea Approved Phase 3 127-07-1 3657
Ethanol Approved Phase 3 64-17-5 702
Atezolizumab Approved, Investigational Phase 2, Phase 3 1380723-44-3
Bevacizumab Approved, Investigational Phase 2, Phase 3 216974-75-3 135329020
Sucralfate Approved Phase 3 54182-58-0
Durvalumab Approved, Investigational Phase 2, Phase 3 1428935-60-7
Niacin Approved, Investigational, Nutraceutical Phase 3 59-67-6 938
Folic acid Approved, Nutraceutical, Vet_approved Phase 3 59-30-3 6037
13 Vitamins Phase 3
14 Vitamin B3 Phase 3
15 Nicotinic Acids Phase 3
16 Antimetabolites Phase 3
17 Folate Phase 3
18 Vitamin B9 Phase 3
19 Vasodilator Agents Phase 3
20 Vitamin B Complex Phase 3
21 Hypolipidemic Agents Phase 3
22 Lipid Regulating Agents Phase 3
23 Endothelial Growth Factors Phase 2, Phase 3
24 Aloe Phase 3
25 Anti-Ulcer Agents Phase 3
26 Antacids Phase 3
27 Immunoglobulin G Phase 2, Phase 3
Carboplatin Approved Phase 2 41575-94-4 10339178 38904
Paclitaxel Approved, Vet_approved Phase 2 33069-62-4 36314
Capecitabine Approved, Investigational Phase 2 154361-50-9 60953
31 Raspberry Approved Phase 1, Phase 2
Hyaluronic acid Approved, Vet_approved Phase 2 9004-61-9 53477741
Bortezomib Approved, Investigational Phase 2 179324-69-7 387447 93860
Sargramostim Approved, Investigational Phase 2 123774-72-1
Sorafenib Approved, Investigational Phase 2 284461-73-0 216239
Dasatinib Approved, Investigational Phase 2 302962-49-8 3062316
Acetylcysteine Approved, Investigational Phase 2 616-91-1 581 12035
Lapatinib Approved, Investigational Phase 2 231277-92-2, 388082-78-8 208908
Irinotecan Approved, Investigational Phase 2 97682-44-5, 100286-90-6 60838
Avelumab Approved, Investigational Phase 2 1537032-82-8
Cemiplimab Approved, Investigational Phase 2 1801342-60-8
Nivolumab Approved Phase 2 946414-94-4
Miconazole Approved, Investigational, Vet_approved Phase 2 22916-47-8 4189
Clotrimazole Approved, Vet_approved Phase 2 23593-75-1 2812
Pembrolizumab Approved Phase 2 1374853-91-4 254741536
Doxepin Approved, Investigational Phase 2 1668-19-5 667468 667477
Histamine Approved, Investigational Phase 2 51-45-6 774
Diphenhydramine Approved, Investigational Phase 2 147-24-0, 58-73-1 3100
Promethazine Approved, Investigational Phase 2 60-87-7 4927
Celecoxib Approved, Investigational Phase 2 169590-42-5 2662

Interventional clinical trials:

(show top 50) (show all 198)
# Name Status NCT ID Phase Drugs
1 the Comparison of Voice Quality in Early Laryngeal Cancer Between Surgery and Radiotherapy Unknown status NCT00497588 Phase 3
2 A Multicentre, Randomised, Phase III Clinical Trial Comparing Accelerated Radiotherapy With Accelerated Radiotherapy Plus Carbogen and Nicotinamide (ARCON) in Clinical Stage T2-4 Laryngeal Carcinoma. Completed NCT00147732 Phase 3
3 Double Blind Randomised Study of 2 Days and 5 Days Cefazolin Prophylactic Method in Laryngeal Oncologic Surgery Completed NCT00467948 Phase 3 cefazolin
4 Randomized Study Comparing Induction Chemotherapy With Docetaxel, Cisplatin, 5FU Versus Cisplatin, 5 FU in Patients With T3 and T4 Larynx and Hypopharynx Carcinoma Completed NCT00169182 Phase 3 DOCETAXEL;Cisplatin;5-Fluoro-3-Pyridinecarboxylic Acid
5 Phase III Trial Comparing Conventional RT With Concomitant CT Versus Accelerated RT With Concomitant CT Versus Very Accelerated RT Alone in Patients With Head and Neck Squamous Cell Carcinoma Completed NCT00158652 Phase 3 5FU, Paraplatin
6 A Randomized Trial Evaluating a Very Intense Radiotherapy-Chemotherapy Regimen Versus a Very Accelerated Radiotherapy in Advanced Head and Neck Squamous Cell Carcinoma Completed NCT00162708 Phase 2, Phase 3 CDDP, 5 Fu
7 DEPISTORL - THANCS (Trial of Head And Neck Cancer Screening) Randomized Multicenter Trial to Assess the Impact of a Screening Program for Heavy Alcohol Drinkers and Smokers Treated in Alcohol Addiction Clinics on Upper Aerodigestive Tract Cancer Mortality. Completed NCT00359645 Phase 3
8 A Phase III Randomized Trial of Docetaxel Based Induction Chemotherapy in Patients With N2/N3 Locally Advanced Head and Neck Cancer Completed NCT00117572 Phase 3 docetaxel;cisplatin;hydroxyurea;fluorouracil
9 A Phase II/III Trial of Chemotherapy + Cetuximab vs Chemotherapy + Bevacizumab vs Atezolizumab + Bevacizumab Following Progression on Immune Checkpoint Inhibition in Recurrent/Metastatic Head and Neck Cancers Recruiting NCT05063552 Phase 2, Phase 3 Carboplatin;Cisplatin;Docetaxel
10 Effects of Oral Aloe Vera Juice on Chemotherapy and Radiation-induced Oral Mucositis and Esophagitis: a Single-blind Randomized Controlled Trial Recruiting NCT05369234 Phase 3 Carafate
11 Randomized Phase II/III Trial of Radiotherapy With Concurrent MEDI4736 (Durvalumab) vs. Radiotherapy With Concurrent Cetuximab in Patients With Locoregionally Advanced Head and Neck Cancer With a Contraindication to Cisplatin Active, not recruiting NCT03258554 Phase 2, Phase 3
12 Phase III Randomized Clinical Trial to Compare Results of Concurrent Chemo-radiation With Surgery and Postoperative Radiotherapy/Chemoradiotherapy in Advanced Laryngeal and Hypopharyngeal Cancers Terminated NCT00128817 Phase 3
13 Phase II Organ Preservation Trial Using Cisplatin Concomitant With Radiation Therapy in Advanced Laryngeal Cancer Patients Who Have Responded to Induction Chemotherapy With Taxotere, Cisplatin, and 5-Fluorouracil (TPF) Unknown status NCT01073683 Phase 2 Taxotere (Docetaxel), Cisplatin, 5FU
14 A Phase II Study of Induction Chemotherapy Followed by Concomitant Paclitaxel (1 Hour Infusion), Fluorouracil, Hydroxyurea and Hyperfractionated Radiotherapy for Advanced Oral, Pharynx and Larynx Cancer Unknown status NCT00004094 Phase 2 carboplatin;fluorouracil;hydroxyurea;paclitaxel
15 Resistance Training During Radiation Therapy for Pharyngeal or Laryngeal Cancer Completed NCT00827164 Phase 2
16 Clinical Outcomes Modeling for Laryngectomy Surgery Patients and Efficacy of Hyperbaric Oxygen Therapy Completed NCT00026975 Phase 2
17 Concomitant Chemotherapy AND Bcl-xL Inhibitor (AT-101) For Bio-selection For Organ Preservation In Patients With Advanced Laryngeal Cancer Completed NCT01633541 Phase 2 AT-101;Docetaxel;Cisplatin;Carboplatin
18 Combination of Cryosurgey and NK Immunotherapy for Recurrent Laryngeal Cancer Completed NCT02849314 Phase 1, Phase 2
19 Phase 1-2 18F-FPPRGD2 PET/CT or PET/MRI Imaging of αvβ3 Integrins Expression as a Biomarker of Angiogenesis Completed NCT01806675 Phase 1, Phase 2 18F-fludeoxyglucose (18F-FDG);18F-FPPRGD2
20 Food-Based Modulation of Biomarkers in Human Tissues at High-Risk for Oral Cancer Completed NCT01469429 Phase 1, Phase 2 chemoprevention
21 Injection Thyroplasty During Transoral Laser Microsurgery for Early Glottic Cancer: Single-blinded Randomized Controlled Trial Completed NCT04525066 Phase 2 Hyaluronic acid
22 A Phase II, Randomized, Open-Label, Single Center Study In Patients With Advanced Head And Neck Cancer To Investigate Efficacy And Safety Of Standard Chemoradiation And Add-On Concurrent Cetuximab ± Consolidation Cetuximab Completed NCT01435252 Phase 2 Cetuximab
23 Randomised Phase II Study of GM-CSF to Reduce Severity of Mucositis Caused by Accelerated Radiotherapy of Laryngeal Cancer Completed NCT00004256 Phase 2
24 Adaptive, Image-guided, Intensity-modulated Radiotherapy for Head and Neck Cancer in the Reduced Volumes of Elective Neck: a Multicenter, Two-arm, Randomized Phase II Trial. Completed NCT01287390 Phase 2
25 A Phase II Trial With Radiotherapy Plus Cetuximab to Evaluate Specific Survival Free of Laryngectomy in Patients With Resectable and Locally Advanced Larynx Cancer, After Treatment With TPF Completed NCT00765011 Phase 2 TPF, radiotherapy and cetuximab
26 A Prospective Non-Inferiority Trial of the Use of Adaptive Radiotherapy for Head and Neck Cancer Undergoing Radiation Therapy Completed NCT03096808 Phase 2
27 Larynx Preservation With Induction Chemotherapy (Cisplatin, 5FU, Docetaxel) Followed by Radiotherapy Combined With Either Cisplatin or Cetuximab in Laryngopharyngeal Squamous Cell Carcinoma - A Randomised Phase II Study Completed NCT00169247 Phase 2 cetuximab;Cisplatin
28 F-18 Fluorothymidine (FLT) PET Imaging for Early Evaluation of Response to Chemoradiation Therapy in Patients With Head and Neck Squamous Cell Carcinoma (HNSCC) Completed NCT00721799 Phase 2 18F-Fluorothymidine PET scan
29 Investigating the Impact of Tailored Reports on Anxiety Completed NCT00127465 Phase 1, Phase 2
30 Randomised Phase II Pilot Study: Induction Chemotherapy With Docetaxel, Cisplatin and Cetuximab Versus Docetaxel, Cisplatin and 5 FU Followed by Radiotherapy With Cetuximab for Locally Advanced or Not Resectable Carcinoma of the Head and Neck Completed NCT01884259 Phase 2 Docetaxel;Cisplatin;5-fluorouracil
31 Phase II Trial Of Induction Chemotherapy Followed By Attenuated Chemoradiotherapy For Locally Advanced Head And Neck Squamous Cell Carcinoma Associated With Human Papillomavirus (HPV) Completed NCT02048020 Phase 2 paclitaxel;carboplatin
32 A Phase 2 Study of Dasatinib in Head and Neck Squamous Cell Carcinoma Completed NCT00507767 Phase 2 dasatinib
33 Phase II Study of Concomitant Fluorouracil, Hydroxyurea, Cetuximab and Hyperfractionated Intensity Modulated Radiation Therapy for Locally Advanced Head and Neck Cancer Completed NCT00462735 Phase 2 Cetuximab;Hydroxyurea;Fluorouracil
34 A Phase II Study of AZD0530 for Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) Completed NCT00513435 Phase 2 saracatinib
35 A Randomized Phase II Trial of Bevacizumab to Control Brain Radiation Damage Completed NCT00492089 Phase 2 bevacizumab;placebo
36 Phase II Study of Sunitinib Malate in Head and Neck Squamous Cell Carcinoma Completed NCT00387335 Phase 2 sunitinib malate
37 Multicenter Randomized Phase II Study of Erlotinib, Cisplatin and Radiotherapy Versus Cisplatin and Radiotherapy in Patients With Stage III and IV Squamous Cell Carcinoma of the Head and Neck Completed NCT00410826 Phase 2 erlotinib hydrochloride;cisplatin
38 A Randomized, Double-Blind Pilot Study of N-Acetylcysteine Mucoadherent Rinse Versus Placebo for Thickened Secretions and Mucositis Secondary to Chemoradiotherapy in the Management of Head and Neck Malignancies Completed NCT02123511 Phase 2 acetylcysteine
39 A Phase 2 Trial of GW572016 in Patients With Metastatic and Recurrent Squamous Cell Carcinomas of the Head and Neck Completed NCT00114283 Phase 2 lapatinib ditosylate
40 Phase II Two Arm Trial of the Proteasome Inhibitor, PS-341 (Velcade TM) in Combination With Irinotecan or PS-341 Alone Followed by the Addition of Irinotecan at Time of Progression in Patients With Locally Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN) Completed NCT00103259 Phase 2 bortezomib;irinotecan hydrochloride
41 A Phase II Study Of GW572016 In Squamous Cell Carcinoma Of The Head And Neck (SCCHN) Completed NCT00098631 Phase 2 lapatinib ditosylate
42 A Phase I and Phase II Study of OSI-774 in Combination With Docetaxel in Squamous Cell Carcinoma of the Head and Neck Completed NCT00055770 Phase 1, Phase 2 erlotinib hydrochloride;docetaxel
43 Phase I/II Dose Escalation Trial of Induction and Concomitant Erlotinib and Celecoxib With Radiation Therapy for Treatment of Poor Prognosis Head and Neck Cancer, Including Reirradiation Completed NCT00970502 Phase 1, Phase 2 erlotinib + celecoxib
44 Phase II Evaluation of BAY 43-9006 (NSC-724772) in Patients With Recurrent or Metastatic Head and Neck Cancer Completed NCT00096512 Phase 2 sorafenib tosylate
45 A Phase 2 Study of SB-715992 in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Completed NCT00095628 Phase 2 ispinesib
46 A Randomized Phase II Study of BMS-247550 (NSC #710428) Given Daily x 5 Days Every 3 Weeks or Weekly in Patients With Metastatic or Recurrent Squamous Cell Cancer of the Head and Neck Completed NCT00033618 Phase 2 ixabepilone
47 Phase II Randomized Trial of the Combination of Cetuximab and Sorafenib or Single Agent Cetuximab in Patients With Refractory, Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN) Completed NCT00939627 Phase 2 sorafenib tosylate
48 A Phase II Study of Capecitabine and Lapatinib in Squamous Cell Carcinoma of the Head and Neck Completed NCT01044433 Phase 2 lapatinib ditosylate;capecitabine
49 A Phase I, and Biologic Correlative Study of Erlotinib, in Combination With Cetuximab and Bevacizumab in Patients With Metastatic Renal Cell Carcinoma Completed NCT00101348 Phase 1, Phase 2 erlotinib hydrochloride
50 A Pharmacogenetic and Pharmacodynamic Study of Erlotinib (OSI-774) Toxicity in Patients With Advanced Solid Tumors Completed NCT00063895 Phase 1, Phase 2 erlotinib hydrochloride

Search NIH Clinical Center for Larynx Cancer

Cochrane evidence based reviews: laryngeal neoplasms

Genetic Tests for Larynx Cancer

Anatomical Context for Larynx Cancer

Organs/tissues related to Larynx Cancer:

FMA: Larynx
MalaCards : Lymph Node, Lung, Trachea, Endothelial, Thyroid, Breast, Liver

Publications for Larynx Cancer

Articles related to Larynx Cancer:

(show top 50) (show all 9877)
# Title Authors PMID Year
Regulation of the cell cycle gene, BTG2, by miR-21 in human laryngeal carcinoma. 62 46
19546886 2009
Laryngeal carcinoma lymph node metastasis and disease-free survival correlate with MASPIN nuclear expression but not with EGFR expression: a series of 108 cases. 53 62
20052590 2010
SH3GL2 gene participates in MEK-ERK signal pathway partly by regulating EGFR in the laryngeal carcinoma cell line Hep2. 53 62
20512084 2010
Expression of Epidermal Growth Factor Receptor variant III in laryngeal carcinoma tissues. 53 62
19427146 2009
[Expression of E-cadherin and uPA and their prognostic value in carcinoma of human larynx.]. 53 62
20193619 2009
EGFR immunoexpression and peripheral blood cytokine secretion as potential biomarkers of tumor behavior in laryngeal squamous cell carcinoma. 53 62
19789511 2009
Potential role of Notch1 signaling pathway in laryngeal squamous cell carcinoma cell line Hep-2 involving proliferation inhibition, cell cycle arrest, cell apoptosis, and cell migration. 53 62
19724860 2009
Laryngeal cancer risk associated with smoking and alcohol consumption is modified by genetic polymorphisms in ERCC5, ERCC6 and RAD23B but not by polymorphisms in five other nucleotide excision repair genes. 53 62
19444904 2009
[Expression of EMS1 protein and its clinical significance in laryngeal carcinoma]. 53 62
19947248 2009
[Relationships of human laryngeal squamous cell carcinomas with the expression of VEGF-C and VEGFR-3]. 53 62
19813623 2009
The role of p53, PCNA and Ki-67 as outcome predictors in the treatment of laryngeal cancer. 53 62
20108544 2009
Impact of EGFR immunoexpression on STAT3 activation and association with proinflammatory/regulatory cytokine pattern in laryngeal squamous cell carcinoma. 53 62
19148533 2009
Radiotherapy in laryngeal carcinoma: can a panel of 13 markers predict response? 53 62
19160427 2009
[Impact of tobacco smoking on biologic background of laryngeal squamous cell carcinoma]. 53 62
20301890 2009
Adhesion/growth-regulatory tissue lectin galectin-1 in relation to angiogenesis/lymphocyte infiltration and prognostic relevance of stromal up-regulation in laryngeal carcinomas. 53 62
19331133 2009
Galectin-3 upregulation during tumor progression in head and neck cancer. 53 62
18677282 2008
Retinoblastoma gene abnormalities in early laryngeal cancer. 53 62
18172658 2008
MASPIN subcellular localization and expression in oral cavity squamous cell carcinoma. 53 62
18236066 2008
[Relative factors analysis including carcinoma marker, molecular margin and clinical factors on laryngeal carcinoma recurrence]. 53 62
18800676 2008
Prognostic value of expression of p53, proliferating cell nuclear antigen, and c-erbB-2 in laryngeal carcinoma. 53 62
18509272 2008
Nuclear localization of mammary serine protease inhibitor (MASPIN): is its impact on the prognosis in laryngeal carcinoma due to a proapoptotic effect? 53 62
18439947 2008
Short hairpin ribonucleic acid targeting the telomerase catalytic unit of messenger ribonucleic acid significantly limits the growth of laryngeal squamous cell carcinoma in nude mice. 53 62
17592663 2008
EGFR, HER2, and HER3 expression in laryngeal primary tumors and corresponding metastases. 53 62
18172732 2008
Clinicopathological significance of the fragile histidine triad transcription protein expression in laryngeal carcinogenesis. 53 62
18357366 2008
Cortactin expression predicts poor survival in laryngeal carcinoma. 53 62
18268491 2008
Inhibition of apoptosis in human laryngeal cancer cells by E6 and E7 oncoproteins of human papillomavirus 16. 53 62
17668439 2008
[Expression of Survivin, Caspase-3 and p53 in surgical margin of laryngeal squamous cell carcinoma and their relationship]. 53 62
18476631 2008
[Expression and implication of CD44 and nm23-H1 proteins in laryngeal carcinoma]. 53 62
18476632 2008
[Expression of FHIT gene protein in laryngeal carcinoma]. 53 62
18476633 2008
[Effect of interferon-gamma on the expression of vascular endothelial growth factor C on Hep-2 laryngeal carcinoma cell lines]. 53 62
18476628 2008
Laryngeal carcinoma recurrence rate and disease-free interval are related to CD105 expression but not to vascular endothelial growth factor 2 (Flk-1/Kdr) expression. 53 62
18383901 2008
Suppression of survivin expression by short hairpin RNA induces apoptosis in human laryngeal carcinoma cells. 53 62
18391576 2008
Application of primary cell cultures of laryngeal carcinoma and laser scanning cytometry in the evaluation of tumor reactivity to cisplatinum. 53 62
18519232 2008
Expression of cyclooxygenase-2, vascular endothelial growth factor and matrix metalloproteinase-2 in patients with primary laryngeal carcinoma: a tissue microarray study. 53 62
17888194 2007
[Relevance of Endoglin (CD105) VEGF and p53 with invasion metastasis and prognosis of laryngeal carcinoma]. 53 62
18330257 2007
Soluble EMMPRIN (extra-cellular matrix metalloproteinase inducer) stimulates the migration of HEp-2 human laryngeal carcinoma cells, accompanied by increased MMP-2 production in fibroblasts. 53 62
18431027 2007
[Correlation of membrane type I matrix metalloproteinase (MT1-MMP) expression with clinicomorphological features of tumor front in squamous cell carcinoma of the larynx]. 53 62
18080692 2007
[The expression of MMP-2, E-cadherin in supraglottic carcinoma and their relationship with cervical lymph node metastasis]. 53 62
18062285 2007
[Expression and role of survivin in laryngeal squamous cell carcinoma and laryngeal papilloma in adults]. 53 62
17634026 2007
[Elemene in the treatment of the transplantable model of human laryngeal squamous carcinoma in nude mice]. 53 62
17634027 2007
[Morphological tumor front grading and matrix metalloproteinases type I expression as a prognostic parameter of the presence of lymph node micrometastases in laryngeal carcinoma]. 53 62
18552024 2007
[Assay of matrix metalloproteinase levels and their endogenous inhibitors in patients with laryngeal carcinoma]. 53 62
17649730 2007
The role of host immune response and apoptosis in patients with laryngeal squamous cell carcinoma. 53 62
17264532 2007
Prognostic significance of metallothionein, p53 protein and Ki-67 antigen expression in laryngeal cancer. 53 62
17352251 2007
Overexpression of human 27 kDa heat shock protein in laryngeal cancer cells confers chemoresistance associated with cell growth delay. 53 62
16906418 2007
Maspin nuclear localization is related to reduced density of tumour-associated micro-vessels in laryngeal carcinoma. 53 62
17214364 2006
5-fluorouracil mediates apoptosis and G1/S arrest in laryngeal squamous cell carcinoma via a p53-independent pathway. 53 62
17207318 2006
[Quantitative analysis of epidermal growth factor receptor mRNA in laryngeal carcinoma by reverse transcription-real time polymerase chain reaction with TagMan probe]. 53 62
17190429 2006
[Relationship among lymphangiogenesis, vascular endothelial growth factor-C mRNA expression and cervical lymphatic metastasis in laryngeal carcinoma]. 53 62
17039808 2006
Human papillomavirus and Epstein-Barr virus infection, p53 expression, and cellular proliferation in laryngeal carcinoma. 53 62
16891205 2006

Variations for Larynx Cancer

Expression for Larynx Cancer

Search GEO for disease gene expression data for Larynx Cancer.

Pathways for Larynx Cancer

Pathways related to Larynx Cancer according to GeneCards Suite gene sharing:

(show all 19)
# Super pathways Score Top Affiliating Genes
Show member pathways
3 12.34 TP53 MKI67 GSTP1 CCND1
Show member pathways
12.03 TP53 EGFR CCND1 BCL2
5 11.8 TP53 EGFR CCND1 BCL2
6 11.79 TP53 CCND1 BCL2
7 11.76 TP53 CCND1 BCL2
8 11.72 TP53 CCND1 BCL2
9 11.62 TP53 TERT NME1
10 11.6 GSTM1 CCND1 BCL2
Show member pathways
11.58 MIR486-1 MIR145 MIR143
13 11.43 MIR21 MIR145 MIR106B
Show member pathways
15 11.12 TP53 TERT EGFR CCND1
Show member pathways
17 10.93 TP53 EGFR CCND1
18 10.93 TP53 MIR21 MIR145 MIR143 MIR106B CCND1
19 10.21 TP53 BCL2

GO Terms for Larynx Cancer

Cellular components related to Larynx Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 RISC complex GO:0016442 9.5 MIR486-1 MIR31 MIR21 MIR148A MIR145 MIR143

Biological processes related to Larynx Cancer according to GeneCards Suite gene sharing:

(show all 27)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of apoptotic process GO:0043066 10.32 TP53 TERT MIR21 GSTP1 EGFR BCL2
2 cellular response to hypoxia GO:0071456 10.09 TP53 TERT MIR106B BCL2
3 positive regulation of G1/S transition of mitotic cell cycle GO:1900087 10.08 CCND1 EGFR TERT
4 glutathione metabolic process GO:0006749 10.06 GSTP1 GSTM3 GSTM1
5 positive regulation of angiogenesis GO:0045766 10.02 TERT MIR31 MIR21 MIR143
6 positive regulation of miRNA transcription GO:1902895 10.01 TP53 TERT EGFR
7 negative regulation of miRNA maturation GO:1903799 9.93 TP53 TERT
8 regulation of ERK1 and ERK2 cascade GO:0070372 9.89 MIR145 GSTP1 EGFR
9 cellular detoxification of nitrogen compound GO:0070458 9.88 GSTM3 GSTM1
10 cell population proliferation GO:0008283 9.88 BCL2 CCND1 EGFR MKI67 TP53
11 B cell lineage commitment GO:0002326 9.86 TP53 BCL2
12 nitrobenzene metabolic process GO:0018916 9.84 GSTM1 GSTM3
13 glutathione derivative biosynthetic process GO:1901687 9.83 GSTM1 GSTP1
14 negative regulation of angiogenesis GO:0016525 9.81 MIR21 MIR145 MIR143 MIR106B
15 response to UV-A GO:0070141 9.78 EGFR CCND1
16 T cell lineage commitment GO:0002360 9.77 TP53 BCL2
17 miRNA-mediated gene silencing GO:0035195 9.77 MIR486-1 MIR31 MIR21 MIR148A MIR145 MIR143
18 angiotensin-activated signaling pathway GO:0038166 9.63 MIR145 MIR143
19 negative regulation of cardiac muscle cell apoptotic process GO:0010667 9.63 MIR21 MIR145 MIR106B
20 positive regulation of miRNA maturation GO:1903800 9.61 TP53 EGFR
21 negative regulation of mitotic cell cycle GO:0045930 9.61 TP53 MIR21 BCL2
22 aorta smooth muscle tissue morphogenesis GO:0060414 9.57 MIR145 MIR143
23 positive regulation of vascular associated smooth muscle cell migration GO:1904754 9.56 TERT MIR21 MIR143
24 regulation of phenotypic switching GO:1900239 9.37 MIR145 MIR143
25 positive regulation of cellular response to hypoxia GO:1900039 9.32 MIR21 MIR145
26 establishment or maintenance of cell type involved in phenotypic switching GO:0044663 9.16 MIR145 MIR143
27 miRNA-mediated gene silencing by inhibition of translation GO:0035278 9.02 MIR31 MIR21 MIR148A MIR145 MIR106B

Molecular functions related to Larynx Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 glutathione transferase activity GO:0004364 9.63 GSTM1 GSTM3 GSTP1
2 mRNA 3'-UTR binding GO:0003730 9.61 TP53 MIR486-1 MIR31 MIR21 MIR145 MIR143
3 mRNA base-pairing translational repressor activity GO:1903231 9.23 MIR486-1 MIR31 MIR21 MIR148A MIR145 MIR143

Sources for Larynx Cancer

8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
27 GO
28 GTR
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
36 LifeMap
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
70 Tocris
72 UMLS via Orphanet
Loading form....